Abiopharma

AXOGEN, INC. (AXGN)

Symbol	AXGN
Name	AXOGEN, INC.
Sector	HEALTH CARE
Region	North America
Industry	Biotechnology: Electromedical & Electrotherapeutic Apparatus
Address	13631 PROGRESS BOULEVARD,SUITE 400, ALACHUA, Florida, 32615, United States
Telephone	+1 386 462-6800
Fax	—
Email	—
Website	https://www.axogeninc.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	—
Description	Axogen (AXGN) is the leading Company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven, and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. Additional info from NASDAQ: Axogen (AXGN) is the leading Company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven, and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.

2026-04-14 11:00

Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026

2026-03-26 17:11

New Form SCHEDULE 13G/A - Axogen, Inc. Filed: 2026-03-26 AccNo: 0000102909-26-000787 Size: 7 KB

2026-03-18 20:11

DeVinney Erick Wayne 🟡 adjusted position in 27.8K shares (2 derivative) of Axogen, Inc. (AXGN) at $32.84 Transaction Date: Mar 16, 2026 | Filing ID: 000048

2026-03-18 20:10

Hartley Lindsey Marie 🟡 adjusted position in 14.5K shares (2 derivative) of Axogen, Inc. (AXGN) at $32.84 Transaction Date: Mar 16, 2026 | Filing ID: 000047

2026-03-02 23:16

Kemp Jens 🟡 adjusted position in 55.3K shares (1 derivative) of Axogen, Inc. (AXGN) at $31.90 Transaction Date: Feb 26, 2026 | Filing ID: 000044

2026-03-02 23:16

DeVinney Erick Wayne 🟡 adjusted position in 34.8K shares (1 derivative) of Axogen, Inc. (AXGN) at $31.90 Transaction Date: Feb 26, 2026 | Filing ID: 000043

2026-03-02 23:15

Began Marc A 🟡 adjusted position in 66.1K shares (2 derivative) of Axogen, Inc. (AXGN) at $31.90 Transaction Date: Feb 26, 2026 | Filing ID: 000042

2026-02-24 21:26

Hartley Lindsey Marie 🟡 adjusted position in 28.3K shares (1 derivative) of Axogen, Inc. (AXGN) at $35.38 Transaction Date: Feb 22, 2026 | Filing ID: 000032

2026-02-24 18:24

New Form 10-K - Axogen, Inc. Filed: 2026-02-24 AccNo: 0000805928-26-000031 Size: 10 MB

2026-02-24 12:02

(30% Negative) Axogen Inc. (AXGN) Reports Q1 2026 Financial Results

No clinical trials found for this company.

No clinical products found for this company.